Deutsche Venture Capital

About The Fund

Deutsche Venture Capital (DVC) was the corporate venture capital arm of Deutsche Bank focused on providing investment to promising BioTech startups. As a corporate venture entity, DVC operated by allocating financial resources to early-stage companies that showcased significant potential for growth and technological advancements in the biotechnology sector. With an investment range specifying a minimum of $732,000 and capping at a maximum of $30,000,000, they aimed to support innovations that could lead to substantial returns on investment and strategic benefits. Following the venture capital paradigm, they sought opportunities to enter as key investors in various funding rounds, from seed to more advanced stages of a company's life cycle. DVC's approach encapsulated an investment thesis that prioritized scalable business models and disruptive technologies within the BioTech industry. Meanwhile, the fund was known for actively managing its portfolio, providing not only capital but also strategic counseling derived from the vast financial expertise of Deutsche Bank. Ultimately, DVC was acquired by VCG Venture Capital, which indicates a potential shift or expansion in investment strategies post-acquisition. However, due to the acquisition, the fund's original operations, typical of an independent corporate venture arm, might have been integrated or reshaped to align with the objectives and methodologies of VCG Venture Capital.